Independent Financial Group LLC bought a new stake in Bristol Myers Squibb Company (NYSE:BMY – Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 16,100 shares of the biopharmaceutical company’s stock, valued at approximately $976,000.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its stake in shares of Bristol Myers Squibb by 1.4% during the 4th quarter. Vanguard Group Inc. now owns 198,727,768 shares of the biopharmaceutical company’s stock worth $10,719,376,000 after purchasing an additional 2,743,759 shares during the last quarter. State Street Corp grew its holdings in Bristol Myers Squibb by 1.4% during the fourth quarter. State Street Corp now owns 97,980,438 shares of the biopharmaceutical company’s stock worth $5,285,065,000 after purchasing an additional 1,385,206 shares during the period. Geode Capital Management LLC increased its position in Bristol Myers Squibb by 13.1% during the fourth quarter. Geode Capital Management LLC now owns 52,638,346 shares of the biopharmaceutical company’s stock worth $2,837,026,000 after buying an additional 6,084,046 shares during the last quarter. Norges Bank bought a new stake in Bristol Myers Squibb in the fourth quarter valued at approximately $1,947,272,000. Finally, AQR Capital Management LLC raised its stake in Bristol Myers Squibb by 172.6% in the fourth quarter. AQR Capital Management LLC now owns 25,796,905 shares of the biopharmaceutical company’s stock valued at $1,391,485,000 after buying an additional 16,332,924 shares during the period. 76.41% of the stock is owned by institutional investors.
Analysts Set New Price Targets
Several brokerages have recently commented on BMY. Bank of America reduced their target price on Bristol Myers Squibb from $67.00 to $66.00 and set a “buy” rating for the company in a research note on Friday, July 10th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $54.00 price objective on shares of Bristol Myers Squibb in a research report on Monday, July 6th. Citigroup reissued a “neutral” rating on shares of Bristol Myers Squibb in a research report on Friday, May 1st. Wall Street Zen raised shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 27th. Finally, Guggenheim reiterated a “buy” rating and issued a $72.00 price target on shares of Bristol Myers Squibb in a research note on Wednesday, April 8th. Eight equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Bristol Myers Squibb currently has a consensus rating of “Hold” and a consensus target price of $61.25.
Bristol Myers Squibb News Summary
Here are the key news stories impacting Bristol Myers Squibb this week:
- Positive Sentiment: Bristol Myers Squibb expanded its NVIDIA partnership and plans to deploy a DGX SuperPOD based on Vera Rubin systems, which the company says will become the most powerful AI factory in life sciences and should enhance drug discovery and development efficiency. Bristol Myers Expands NVIDIA Partnership to Build Top Life Sciences AI Supercomputer
- Positive Sentiment: The company also said it will be the first life sciences firm to buy Nvidia’s latest DGX SuperPOD system, signaling an aggressive investment in AI infrastructure that could strengthen Bristol Myers’ competitive position in future drug research. Bristol Myers buys Nvidia’s latest AI computing system for drug research
- Neutral Sentiment: A Reuters report repeated the AI-infrastructure news, reinforcing the strategic nature of the announcement but adding no materially new information for investors. Bristol Myers buys Nvidia’s latest AI computing system for drug research
- Neutral Sentiment: Bristol Myers was mentioned in a broader article about cancer-drug competition and next-generation therapies, but the piece mainly discussed the market landscape rather than any company-specific development. Merck’s Keytruda Faces a Patent Cliff. These New Cancer Drugs Could Take Over.
- Negative Sentiment: Healthcare stocks fell late Monday afternoon, which may be creating a modest drag on BMY and offsetting some of the optimism from the NVIDIA partnership news. Sector Update: Healthcare Stocks Fall Late Afternoon
Bristol Myers Squibb Stock Performance
Shares of NYSE BMY opened at $60.30 on Tuesday. The company has a debt-to-equity ratio of 2.10, a current ratio of 1.42 and a quick ratio of 1.28. The firm has a market cap of $123.14 billion, a price-to-earnings ratio of 16.94, a P/E/G ratio of 0.17 and a beta of 0.23. The stock’s fifty day moving average price is $57.11 and its two-hundred day moving average price is $57.85. Bristol Myers Squibb Company has a one year low of $42.52 and a one year high of $62.89.
Bristol Myers Squibb (NYSE:BMY – Get Free Report) last posted its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, topping analysts’ consensus estimates of $1.42 by $0.16. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The company had revenue of $11.49 billion during the quarter, compared to the consensus estimate of $10.93 billion. During the same quarter last year, the firm earned $1.80 earnings per share. The company’s revenue was up 2.6% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, equities analysts forecast that Bristol Myers Squibb Company will post 6.34 EPS for the current year.
Bristol Myers Squibb Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd will be issued a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 4.2%. The ex-dividend date of this dividend is Thursday, July 2nd. Bristol Myers Squibb’s payout ratio is presently 70.79%.
Bristol Myers Squibb Profile
Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.
BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.
Featured Stories
- Five stocks we like better than Bristol Myers Squibb
- The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence
- Is Domino’s Stock Serving Up a Buying Opportunity?
- A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free
- Why Gold Miners Could Be the Market’s Biggest Comeback Story
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY – Free Report).
Receive News & Ratings for Bristol Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.
